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Purpose:  To  examine  the  association  between  apolipoprotein  E  (APOE)  polymorphisms  and  age-related  macular
degeneration (AMD) in a Chinese population.
Methods: The study consisted of 712 subjects, including 201 controls, 363 cases with early AMD, and 148 cases with
exudative AMD. Genomic DNA was extracted from venous blood leukocytes. Common allelic variants of APOE (ε2,
ε3, and ε4) were analyzed by PCR and direct sequencing.
Results: APOE ε3ε3 was the most frequent genotype, with a frequency of 72.6% in controls, 72.5% in early AMD, and
70.3% in exudative AMD. Frequency of the ε2 allele was 6.7% in controls, 7.4% in early AMD, and 8.8% in exudative
AMD. Frequency of the ε4 allele was 8.7% in controls, 7.7% in early AMD, and 7.8% in exudative AMD. No statistically
significant difference in APOE genotype and allele frequency distribution was observed among controls, cases with early
AMD, and cases with exudative AMD. For ε2 allele carriers, the odds ratio was 1.12 (95% confidence interval [CI], 0.65–
1.93) for early AMD and 1.06 (95% CI, 0.53–2.10) for exudative AMD. For ε4 allele carriers, the odds ratio was 1.04
(95% CI, 0.61–1.75) for early AMD and 0.83 (95% CI, 0.42–1.62) for exudative AMD.
Conclusions: Our data provide no evidence to support an association of APOE polymorphisms with early or exudative
AMD, suggesting that APOE is less likely to be a major AMD susceptibility gene in the Chinese population.
Age-related  macular  degeneration  (AMD)  causes
irreversible central vision loss and is the leading cause of legal
blindness in the elderly population. Evidence suggests that
AMD is a complex disease caused by actions and interactions
of  multiple  genes  and  environmental  factors  [1-10].
Apolipoprotein E is a transport protein of lipid and cholesterol
in  the  nervous  system,  playing  a  pivotal  role  in  the  re-
innervation process following nervous system injury [11-14].
The  gene  for  apolipoprotein  E  (APOE),  located  on
chromosome 19q13.2, is polymorphic, with three major allelic
variants, ε2, ε3, and ε4 [12,15]. The APOE ε4 allele has been
associated  with  a  variety  of  neurodegenerative  and
cardiovascular  diseases,  most  notably  Alzheimer  disease.
Interestingly, APOE is also a ubiquitous component of drusen
[16-21], a hallmark of early AMD. Various clinical signs of
AMD are also mimicked in APOE knockout [20] or transgenic
animal models [21], suggesting that APOE may play a role in
the pathogenesis of AMD. Several genetic association studies
have shown that the APOE ε4 allele is associated with a
protective effect against AMD [22-28], whereas the ε2 allele
may be weakly associated with an increased risk [16,27-31].
Other  studies,  however,  do  not  support  this  association
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between APOE and AMD [32-37]. Given the inconsistencies
of the previous studies, it was imperative to investigate this
association further. The purpose of this study was to verify the
possible association of APOE polymorphisms with early or
late AMD in an independent cohort of a Chinese population.
METHODS
Subjects and clinical evaluation: This case-control cohort
included 201 control subjects, 363 cases with early AMD, and
148 cases with exudative AMD. Gender and age breakdown
of the controls and cases were given in Table 1. The study
participants were recruited through a community-based eye
disease screening program in urban Beijing and outpatients
visiting the Beijing Tongren Hospital. Subjects aged 50 years
or older with or without signs of early or late AMD were
included  in  the  study.  Exclusion  criteria  included  any
contraindications to pupil dilation, advanced cataract or other
conditions that impeded a clear view of the retina, or patients
with eye diseases, such as glaucoma, uveitis, and chorioretinal
diseases, other than AMD. Patients with diabetes were also
excluded. The study protocol was reviewed and approved by
the  Ethics  Committee  of  the  Beijing  Tongren  Hospital.
Informed consent was obtained from all participants, and the
procedures used conformed to the tenets of the Declaration of
Helsinki for research involving human subjects.
All  subjects  underwent  a  comprehensive
ophthalmological  examination,  including  visual  acuity
measurement, slit-lamp biomicroscopy, and detailed fundus
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997examination after pupil dilation, using 0.5% tropicamide and
5% phenylephrine (Santen Pharmaceutical, Osaka, Japan),
performed  by  a  retinal  specialist.  Smoking  history  was
ascertained  using  a  standard  questionnaire.  Stereoscopic
mydriatic 30° color fundus photographs were taken from both
eyes,  using  a  digital  fundus  camera  (Zeiss  Oberkochen,
Oberkochen,  Germany)  centered  on  the  fovea.  Fundus
photographs were assessed by two independent readers, and
a retinal specialist was used as a third person to make final
judgment  in  case  of  any  discrepancies.  Early  AMD  was
defined  as  the  presence  of  soft  drusen  (>63  µm)  with  or
without pigment abnormalities [24]. Individuals with only
hard drusen (classified as drusen <63 µm in size) or with only
pigmentary changes were not classified as having AMD as it
was imperative to be able to classify individuals as positive
for disease with certainty. Individuals were selected as control
subjects based on the presence of normal fundus or having
only a few (less than ten) hard drusen in both eyes [24,38].
Patients with late AMD were examined and confirmed by
fluorescein and/or indocyanine green fundus angiography.
Apolipoprotein E genotyping: Blood samples were collected
from  all  participants  and  stored  at  −80  °C  before  DNA
extraction. Genomic DNA was isolated from venous blood
leukocytes using a genomic DNA extraction and purification
kit (TIANamp Swab DNA Kit; Tiangen Biotech, Beijing,
China) according to the manufacturer’s protocol. Briefly, lysis
buffer was added to blood samples, mixed, and the tubes
centrifuged.  The  supernatant  was  discarded  and  pellet  re-
suspended in a solution of proteinase K and sodium dodecyl
sulfate.  The  mixture  was  incubated  at  65  °C  for  30  min.
Genomic DNA was precipitated by isopropanol, rinsed with
ethanol, and finally re-suspended in TE buffer (1M Tris-HCl;
0.5M EDTA; pH 8.0). PCR amplification was undertaken in
a GeneAmp PCR 9700 thermal cycler (Applied Biosystems,
Foster  City,  CA).  A  241-bp  PCR  product  encompassing
amino acid position 112 was produced by using the forward
primer 5′-GCC TCC CAC TGT GCG A-3′ and the reverse
primer 5′-GGC CGA GCA TGG CCT G-3′. A 150-bp product
encompassing amino acid position 158 was produced by using
the forward primer 5′-ACC GAG GAG CTG CGG G-3′ and
the reverse primer 5′-CTC GCG GAT GGC GCT GA-3′. PCR
conditions  used  for  amplification  were  94  °C  for  5  min,
followed by 40 cycles of 94 °C for 30 s, 65 °C for 30 s, and
72  °C  for  30  s.  The  final  extension  step  at  72  °C  was
lengthened  to  10  min.  PCR  products  were  then  directly
sequenced using an automatic ABI 3730XL DNA Analyzer
(Applied  Biosystems).  Single  nucleotide  polymorphisms
(SNPs) at amino acid position 112 (C112R or c.388T>C of
GenBank reference sequence NM000041.2) and 158 (R158C
or c.526C>T of reference sequence NM000041.2) were then
used to determine the APOE allelic variants ε2 (112C, 158C),
ε3 (112C, 158R, reference sequence NM000041.2), and ε4
(112R, 158R).
Statistical  analysis:  The  data  were  analyzed  using  the  R
statistical  analysis  package.  Hardy–Weinberg  equilibrium
was assessed using the chi-square test comparing observed
with expected proportions. Distributions of APOE genotypes
(ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε4, ε4ε4) and alleles (ε2, ε3, ε4)
were analyzed using the χ2 test and Fisher’s exact test when
the expected frequency was <5. We defined carriers of the ε2
allele to include genotypes ε2ε2 and ε2ε3 and carriers of the
ε4 allele to include genotypes ε3ε4 and ε4ε4. Individuals with
TABLE 1. CHARACTERISTICS OF STUDY SUBJECTS.
    Cases with AMD
Age (years) Controls (n=201) Early AMD (n=363) Exudative AMD (n=148)
mean±SD 63.7±7.6 67.2±7.5 65.6±8.6
Range 50 - 84 50 - 84 50 - 89
Age group
50–54 21 (10.4%) 20 (5.5%) 14 (9.5%)
55–59 52 (25.9%) 37 (10.2%) 27 (18.2%)
60–64 50 (24.9%) 82 (22.6%) 24 (16.2%)
65–69 23 (11.4%) 77 (21.2%) 39 (26.4%)
≥70 55 (27.4%) 147 (40.5%) 44 (29.7%)
Gender
Female 138 (68.7%) 233 (64.2%) 56 (37.8%)
Male 63 (31.3%) 130 (35.8%) 92 (62.2%)
Cigarette Smoking
Never 153 (76.1%) 284 (78.2%) 80 (54.1%)
Past 24 (11.9%) 44 (12.1%) 31 (20.9%)
Current 24 (11.9%) 35 (9.6%) 37 (25.0%)
        This table summarizes the general characteristics of study subjects with or without age-related macular degeneration (AMD).
        SD represents standard deviation.
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998the ε2ε4 genotype were excluded from all analyses to avoid
potential confounding effects. A logistic regression model
was used to calculate the odds ratio (OR) and 95% confidence
interval (CI) of early or late AMD, comparing ε2 or ε4 allele
carriers to the ε3ε3 genotype as the reference, adjusted for age,
gender, and cigarette smoking. A risk score model was used
to  evaluate  the  variation  in  APOE  polymorphisms,  as
suggested  in  the  literature  [37].  Briefly,  the  model
respectively assigned +1, 0, or −1 per ε2, ε3, or ε4 allele. As
a result, the genotypes of ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε4, and
ε4ε4 will respectively have scores of +2, +1, 0, 0, −1, and −2.
The statistically significant level was set at p<0.05.
RESULTS
A total of 712 subjects participated in the study, including 201
control subjects, 363 cases with early AMD in one or both
eyes, and 148 cases with exudative AMD in at least one eye.
Fluorescein angiography was undertaken in all cases with
exudative  AMD,  and  indocyanine  green  angiography  was
available in 42 cases. No atrophic AMD patient was identified
among the study participants. The general characteristics of
the study subjects are given in Table 1.
The APOE genotype and allele frequency distribution
among study subjects are given in Table 2. Frequencies of
APOE genotypes were under Hardy–Weinberg equilibrium in
controls and cases with early or exudative AMD (p≥0.099).
The ε3ε3 was the most frequent genotype with a frequency of
72.6%  in  controls,  72.5%  in  early  AMD,  and  70.3%  in
exudative AMD. Frequency of the  ε2 allele was 6.7% in
controls, 7.4% in early AMD, and 8.8% in exudative AMD.
Frequency of the ε4 allele was 8.7% in controls, 7.7% in early
AMD,  and  7.8%  in  exudative  AMD.  No  statistically
significant differences between controls and early AMD or
between controls and exudative AMD were found for any
genotype or allele frequencies.
TABLE 2. APOLIPOPROTEIN E (APOE) GENOTYPE AND ALLELE FREQUENCY DISTRIBUTION AMONG STUDY SUBJECTS.
    Cases with AMD
Genotype Controls Early AMD Exudative AMD
ε2ε2 0 (0) 2 (0.6%) 1 (0.7%)
ε2ε3 24 (11.9) 46 (12.7%) 20 (13.5%)
ε2ε4 3 (1.5%) 4 (1.1%) 4 (2.7%)
ε3ε3 146 (72.6%) 263 (72.5%) 104 (70.3%)
ε3ε4 24 (11.9%) 44 (12.1%) 19 (12.8%)
ε4ε4 4 (2.0%) 4 (1.1%) 0 (0)
Total 201 (100%) 363 (100%) 148 (100%)
P-value — 0.885 0.416
H-W
χ
2 6.265 1.846 2.994
p 0.099 0.605 0.393
Allele
ε2 27 (6.7%) 54 (7.4%) 26 (8.8%)
ε3 340 (84.6%) 616 (84.8%) 247 (83.4)
ε4 35 (8.7%) 56 (7.7%) 23 (7.8%)
Total 402 (100%) 726 (100%) 296 (100%)
p-value — 0.776 0.558
Carrier
ε*2 24 (12.1%) 48 (13.4%) 21 (14.6%)
ε3ε3 146 (73.7%) 263 (73.3%) 104 (72.2%)
ε*4 28 (14.1%) 48 (13.4%) 19 (13.2%)
Total 198 (100%) 359 (100%) 144 (100%)
p-value — 0.899 0.793
         The genotype and allele frequency distributions in controls and cases with early or exudative age-related macular degeneration
         (AMD) are summerized in this table. Data are expressed as number (%). For carriers, the ε*2 group includes genotypes of
         ε2ε2 and ε2ε3, whereas the ε*4 group includes genotypes of ε3ε4 and ε4ε4. Subjects with ε2ε4 genotype (3 in controls, 4 in
         early AMD, 4 in exudative AMD) are excluded from either ε*2 or ε*4 group. P-value represents comparison of genotype or
         allele frequency distribution between cases and controls. H-W represents Hardy–Weinberg equilibrium.
Molecular Vision 2011; 17:997-1002 <http://www.molvis.org/molvis/v17/a111> © 2011 Molecular Vision
999The OR and risk scores of APOE alleles associated with
early or exudative AMD are given in Table 3. After adjustment
for age, gender, and cigarette smoking, the OR for ε2 allele
carriers was 1.12 (95% CI, 0.65–1.93) for early AMD and 1.06
(95%  CI,  0.53–2.10)  for  exudative  AMD.  For  ε4  allele
carriers, the OR was 1.04 (95% CI, 0.61–1.75) for early AMD
and  0.83  (95%  CI,  0.42–1.62)  for  exudative  AMD.  No
association between increasing APOE risk score and early or
exudative AMD was identified.
The power to detect a significant association between the
APOE ε4 or ε2 allele and any AMD was calculated under the
condition of different hypothetical OR values. To detect a
significantly protective effect of the ε4 allele, the sample size
in this study had 83.3% power if the ε4 allele carriers had an
OR of 0.5 and 30.3% power if the ε4 allele carriers had an OR
of 0.7. To detect a significant risk effect of the ε2 allele, the
sample size in this study had 78.0% power if the ε2 allele
carriers had an OR of 2.3 and 26.8% power if the ε2 allele
carriers had an OR of 1.5.
DISCUSSION
The possible relationship between APOE polymorphisms and
AMD has been examined in previous studies, most of which
have  focused  on  late  AMD  in  Caucasian  populations.  In
general,  many  of  these  previous  studies  suggest  that  the
APOE ε4 allele is associated with a lower risk of late AMD
[22-28], whereas less consistently the ε2 allele seems to confer
an  increased  risk  [16,27-31].  This  association  between
APOE  and  AMD,  however,  is  not  always  reproducible.
Several  other  studies  reported  no  evidence  to  support  a
significant  association  between  APOE  and  late  AMD  in
Caucasian [32-34], Hong Kong Chinese [35], and Japanese
[36]  populations.  Moreover,  no  evidence  of  association
between APOE and early AMD was found in a large cohort
of a population-based cross-sectional study in a Caucasian
population [37]. In agreement with a previous report in Hong
Kong Chinese [35], our data provide no evidence to support
a significant association between APOE and exudative AMD.
In addition, no association between APOE and early AMD
was found in this study. In a previous report in Japanese
patients, APOE was not associated with polypoidal choroidal
vasculopathy (PCV) or typical AMD [36]. In this current
study, however, we were not able to differentiate PCV from
typical AMD as the confirmation of PCV is solely based on
indocyanine green angiography, which is not available to the
majority of our patients with exudative AMD.
The  lack  of  a  significant  association  of  APOE
polymorphisms  with  AMD  in  the  current  study  may  be
explained by the small or nonexistent effect of APOE on AMD
in the Chinese population. It should be noted, however, that
the APOE ε4 allele occurs less frequently in Chinese than in
Caucasian control populations, making it more difficult to
detect  the  effect  of  APOE  in  Chinese  individuals.  The
frequency of the ε4 allele was reported to be 12.4%–17.9% in
Caucasian  control  populations  [16,24,25,31,33,34].  In  the
current study, the frequency of ε4 allele was 8.7% in controls,
effectively decreasing the power of our study to replicate the
findings reported in Caucasian populations. The sample size
in this current study had sufficient statistical power to detect
only  a  strong  association  between  APOE  and  AMD.  We
therefore cannot exclude the possibility of a weak association
between  APOE  polymorphisms  and  AMD  in  the  Chinese
population.
In  summary,  we  provide  no  evidence  to  support  a
significant association of APOE polymorphisms with early or
exudative AMD in this study, suggesting that APOE is less
likely to be a major susceptibility gene to AMD in the Chinese
population.  Whether  there  is  a  weak  association  between
TABLE 3. ASSOCIATION BETWEEN APOLIPOPROTEIN E (APOE) AND RISK OF AGE-RELATED MACULAR DEGENERATION (AMD).
AMD APOE OR (95% CI)
Crude Adjusted
Early AMD ε2 carrier 1.11 (0.65 - 1.89) 1.12 (0.65 - 1.93)
ε4 carrier 0.95 (0.57 - 1.58) 1.04 (0.61 - 1.75)
APOE risk score 1.12 (0.82 - 1.52) 1.08 (0.79 - 1.48)
Exudative AMD ε2 carrier 1.23 (0.65 - 2.32) 1.06 (0.53 - 2.10)
ε4 carrier 0.95 (0.51 – 1.80) 0.83 (0.42 – 1.62)
APOE risk score 1.22 (0.83 - 1.79) 1.22 (0.81 - 1.83)
        Logistic regression model was used to calculate odds ratio (OR) and 95% confidence interval (CI) for early or late AMD,
        comparing ε2 or ε4 allele carriers vs ε3ε3 genotype as reference. The ε2 carrier includes genotypes of ε2ε2 and ε2ε3, whereas
        the ε4 carrier includes genotypes of ε3ε4 and ε4ε4. Subjects with ε2ε4 genotype (3 in controls, 4 in early AMD, 4 in exudative
        AMD) are excluded from either ε2 or ε4 carrier. APOE risk scores were evaluated by respectively assigning +1, 0, or −1 per
        ε2, ε3, or ε4 allele. As a result, genotypes of ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε4, and ε4ε4 would have scores of +2, +1, 0, 0, −1, and
        −2, respectively. Data are expressed as OR (95%CI). Adjusted OR represents data after adjustment for age, gender and cigarette
        smoking.
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